Soligenix Inc. (NASDAQ: SNGX) Proprietary Therapy Shows Promise in Treatment of Psoriasis
Psoriasis affects approximately 3% of the adult population in the United States, translating to more than 7.5 million individuals. By using visible light, Soligenix’s SGX302 aims to mitigate risks while effectively reducing inflammation and promoting skin healing. A phase 2a study demonstrated that SGX302 was well tolerated, with no significant adverse events reported. Psoriasis is more than just a skin condition — it’s a lifelong autoimmune disorder that disrupts daily life with painful, inflamed patches and an emotional toll that can be just as severe as the physical symptoms. Soligenix (NASDAQ: SNGX) is at the forefront of developing innovative therapies…







